BIIB Looks 13.8% Overvalued on GF Value™ Following China Approval

gurufocus.com · 2026-09-03

On September 03, 2026, Biogen Inc (NASDAQ: BIIB) and Eisai announced that their subcutaneous Alzheimer's treatment, Leqembi, received regulatory approval from C

Read the full story at gurufocus.com →